Mario Feola
Keine laufenden Positionen mehr
Profil
Mario Feola has been Chief Medical Officer of Hemobiotech, Inc. since November 1, 2004.
From December 14, 2003 to October 31, 2004, he served as Chief Medical Officer on a part-time basis for Hemobiotech.
From 1994 to 2004, Dr. Feola served as the Chief of Surgery at the Veteran's Affairs Hospital in Amarillo, Texas.
Since 1977, he has served as a Professor of Surgery at Texas Tech.
He received an MD from the University of Naples, Italy.
Ehemalige bekannte Positionen von Mario Feola
| Unternehmen | Position | Ende |
|---|---|---|
Hemobiotech, Inc.
 Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mario Feola
| Università degli Studi di Napoli Federico II | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Hemobiotech, Inc.
Hemobiotech, Inc. BiotechnologyHealth Technology HemoBioTech, Inc. is a biopharmaceutical company, that is engaged in the research and development of human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. The company's core product, HemoTech, which is a bovine-hemoglobin based human blood substitute red blood cells in the capable of replacing human body. The company was founded in December 2003 and is headquartered in Dallas, TX. | Health Technology |
